Ken Griffin Eton Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$3.06 - $3.75 $43,452 - $53,250	-14,200 Reduced 49.82%	14,300 $47,000
Q1 2024 May 15, 2024	BUY	$3.48 - $5.03 $44,196 - $63,881	12,700 Added 80.38%	28,500 $106,000
Q4 2023 Feb 14, 2024	SELL	$3.45 - $4.66 $37,950 - $51,260	-11,000 Reduced 41.04%	15,800 $69,000
Q3 2023 Nov 14, 2023	SELL	$2.55 - $5.63 $18,870 - $41,662	-7,400 Reduced 21.64%	26,800 $111,000
Q2 2023 Aug 14, 2023	BUY	$3.32 - $4.04 $50,796 - $61,812	15,300 Added 80.95%	34,200 $119,000
Q1 2023 May 15, 2023	BUY	$2.89 - $4.1 $54,621 - $77,490	18,900 New	18,900 $72,000

8.16M

41K

Ticker ETON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,297,000
Market Cap $145M
Description
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.